Loading
Everything OnCo dates to 1996: 70 entries, 24 landmarks, 11 approvals, 11 papers and 10 papers listed on people's pages. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
70 dated entries in OnCo fall in 1996: 24 landmarks, 11 approvals, 11 papers, 10 papers listed on people's pages, 5 companies founded, 4 journals founded, 2 laws and regulations, 2 trials reported and 1 technology.
Of those, 70 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Severe psoriasis (oncology use as chemoprevention of squamous cell carcinoma is off-label)
Hyperprolactinaemic disorders, idiopathic or due to pituitary adenomas
Recurrent glioblastoma as an adjunct to surgery (Gliadel Wafer); newly diagnosed high-grade glioma with surgery and radiation added 2003
Locally advanced or metastatic breast cancer after chemotherapy (Taxotere, NDA 020449)
Pancreatic cancer
Tumour-induced hypercalcaemia; prevention of skeletal events in breast cancer with bone metastases (Bondronat)
Metastatic colorectal cancer after 5-FU; first line with 5-FU/LV 2000
Metastatic (stage D2) prostate cancer in combination with surgical castration
Metastatic colorectal cancer
Relapsed SCLC (IV)
First-line hormonal treatment of hormone-dependent metastatic breast cancer in postmenopausal women
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
United States, statute.
International, guidance.
The year reported on trial records, with the headline result the record gives.
Colorectal cancer mortality ratio 0.82 (95% CI 0.68 to 0.99) over ten years, with unchanged incidence.
Colorectal cancer deaths 360 in the screened group against 420 in the control group, a 15 percent reduction in cumulative mortality (odds ratio 0.85, 0.74 to 0.98, p = 0.026).
The publication year on key paper records.
Wattel E, Guerci A, Hecquet B, et al. Blood.
Duvic M, Lemak NA, Valero V, et al. Journal of the American Academy of Dermatology.
Bischoff JR, Kirn DH, Williams A, et al. Science.
Omenn GS, Goodman GE, Thornquist MD, et al. New England Journal of Medicine.
Lefebvre JL, Chevalier D, Luboinski B, et al. JNCI: Journal of the National Cancer Institute.
Leach DR, Krummel MF, Allison JP. Science.
Mazzaferro V, Regalia E, Doci R, et al. New England Journal of Medicine.
Mentzel T, Calonje E, Wadden C, et al. American Journal of Surgical Pathology.
Roa I, Araya JC, Villaseca M, et al. Gastroenterology.
Hardcastle JD, Chamberlain JO, Robinson MH, et al. The Lancet.
Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. The Lancet.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Lung cancer (all types). CARET gave beta carotene and retinol to 18,314 smokers and asbestos workers and was stopped 21 months early: relative risk of lung cancer 1.28 and of lung...
High-grade serous ovarian cancer
HIV-associated (AIDS-related) lymphomas. Incidence of AIDS-related NHL falls sharply; survival after lymphoma improves as immune function is preserved.
Kaposi sarcoma
Stage III melanoma (after surgery)
Hypopharyngeal cancer
FLT3-mutated acute myeloid leukaemia
SHH-activated medulloblastoma
Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms. GFM randomised trial (Wattel et al., Blood).
Newly diagnosed multiple myeloma, transplant-eligible
Multiple myeloma
Early hepatocellular carcinoma (BCLC 0 and A)
Hepatocellular carcinoma. Mazzaferro: ~70% five-year survival for small tumours.
Standard-risk B-cell acute lymphoblastic leukaemia in children
Ovarian cancer
Ovarian cancer
Basal cell carcinoma. Hahn et al. and Johnson et al.: links human BCC to the Drosophila hedgehog pathway.
Locally advanced and metastatic basal cell carcinoma
Retinoblastoma
Platinum-resistant ovarian cancer
Small-cell lung cancer
Extensive-stage small-cell lung cancer
Anal cancer (squamous cell carcinoma)
Localised anal squamous cell carcinoma (stage I to III)
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Cologne
Siena
Boston, MA
Oxford
Silver Spring, MD
The founded year on journal records.
SAGE Publications (formerly Mary Ann Liebert)
Springer (Springer Japan)
Springer Nature
Oxford University Press
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Annals of Internal Medicine
Stroke
Cell
The Lancet
Science
Journal of Clinical Oncology
Blood
Annals of Surgery
Pediatric Hematology and Oncology
Journal of Cancer Research and Clinical Oncology